Liver transplantation for homozygous familial hypercholesterolaemia

S P Revell, G Noble-Jamieson, P Johnston, A Rasmussen, N Jamieson, N D Barnes

Abstract
Homozygous familial hypercholesterolaemia is a rare inherited condition with an incidence of approximately one in a million. It is associated with severe premature atherosclerosis and early death from cardiovascular complications. The results of liver transplantation reported to date have suggested only partially effective reduction of the hypercholesterolaemia.

Three boys with familial hypercholesterolaemia, aged 10-0 to 15-1 years, received liver grafts at Addenbrooke's Hospital. Their untreated fasting lipid concentrations were grossly raised. All three had angiographic evidence of coronary atheroma and two had exertional angina. One child had such severe atheroma that coronary artery bypass surgery was considered necessary before liver transplantation. All three had straightforward operative and postoperative courses and their lipid concentrations returned rapidly to normal. One boy developed chronic rejection requiring retransplantation. Currently all three boys are well, on normal diets, and with normal liver function.

It is concluded that (1) liver transplantation offers highly effective treatment for this lethal condition, (2) timing the operation is difficult but it should be undertaken before coronary artery disease has progressed too far (when combined liver and heart transplantation may be the only possibility), and (3) in well grown children with no previous abdominal surgery the immediate risks of liver transplantation are low but chronic rejection remains a danger.

Keywords: liver transplantation, familial hypercholesterolaemia.

Liver transplantation is an established treatment for end stage liver disease in children and has a good medium term success rate. A number of hereditary metabolic conditions may also be cured or relieved by liver transplantation. Homozygous familial hypercholesterolaemia is a rare inherited condition in which affected children develop severe premature atherosclerosis and die from consequent vascular problems. No safe, effective medical treatment is currently available.1 Liver transplantation has the potential to correct the metabolic abnormality but the results reported to date have been equivocal with only partial correction of the lipid abnormality.2

We describe three children in whom liver transplantation fully corrected the lipid abnormality.

Case reports
PATIENT 1
This English boy developed xanthomata at 11 months of age and was found to have the typical lipid profile of homozygous familial hypercholesterolaemia. Initially he was treated with a low fat diet only but from the age of 9 years cholestyramine and nicotinic acid were added. Coronary angiography was normal at that time but when repeated four years later showed a 30% stenosis of the proximal left descending coronary artery. He remained asymptomatic and no ischaemic changes were seen on an electrocardiogram (ECG). His treatment was intensified and for two years he had weekly plasma exchanges. Although this produced a satisfactory fall in lipid concentrations he found the treatment extremely burdensome and it was complicated by multiple central line infections. He was therefore referred for consideration of liver transplantation.

He received a whole liver graft in October 1990 and had an uncomplicated perioperative course. The donor was cytomegalovirus positive and the patient developed cytomegalovirus hepatitis which resolved fully after a course of ganciclovir. His lipid profile and liver function returned to normal two weeks after transplantation (table and figure). He was well and had a normal lipid profile and normal liver function 3-8 years after the operation.

PATIENT 2
This Asian son of a first cousin marriage developed xanthomata at the age of 6 years and was found to have familial hypercholesterolaemia. In spite of treatment with a low fat diet, cholestyramine and simvastatin, his cholesterol remained greatly raised. Coronary angiography at the age of 9 showed atheromatosus changes of the left coronary artery and the descending aorta and also a 50-70% stenosis of the inferior mesenteric artery. There was a chronic dissection of the aorta below the renal arteries which was presumed to have occurred as a complication of angiography. He was referred for transplantation.

He received a whole liver graft in April 1992 and made a rapid recovery. He was hypertensive postoperatively and required treatment with nifedipine and atenolol. His lipid concen-
Liver transplantation for homozygous familial hypercholesterolaemia

Serum lipid concentrations* at diagnosis, assessment, and after liver transplantation (all values are mmol/l)

<table>
<thead>
<tr>
<th></th>
<th>Before transplant</th>
<th>After transplant</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Diagnosis</td>
<td>Assessment</td>
</tr>
<tr>
<td><strong>Patient 1</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>18.0</td>
<td>20.8</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>1.8</td>
<td>0.8</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>19.2</td>
<td>19.2</td>
</tr>
<tr>
<td><strong>Patient 2</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>20.0</td>
<td>25.6</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>2.0</td>
<td>2.0</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>0.5</td>
<td>0.5</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>24.2</td>
<td>24.2</td>
</tr>
<tr>
<td><strong>Patient 3</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total cholesterol</td>
<td>NA</td>
<td>23.9</td>
</tr>
<tr>
<td>Triglyceride</td>
<td>0.8</td>
<td>0.8</td>
</tr>
<tr>
<td>HDL cholesterol</td>
<td>0.7</td>
<td>0.7</td>
</tr>
<tr>
<td>LDL cholesterol</td>
<td>22.9</td>
<td>22.9</td>
</tr>
</tbody>
</table>

*Normal ranges – total cholesterol (mmol/l): desirable <5.2, abnormal >7.8; triglyceride (mmol/l): desirable <2.0, abnormal >4.0; HDL cholesterol (mmol/l): desirable >1.0, abnormal <0.9; LDL cholesterol (mmol/l): desirable <4.0, abnormal >5.5.

Patients 1, 2, and 3 had normal serum lipid values before transplantation. Postoperatively, they showed a gradual reduction in total cholesterol. Patient 3, who had the most severe hypercholesterolaemia, showed the most pronounced reduction. Patient 1 developed angina postoperatively and was discharged after 6 months. Patient 2 developed liver failure and was retransplanted after 6 months. Patient 3 developed liver failure and was retransplanted after 6 months.

All three children had normal graft function and normal blood lipid concentrations.

**Discussion**

Family hypercholesterolaemia is caused by a mutant gene on chromosome 19 coding for the structure of the LDL receptor. This gene is found in approximately one in 500 of the population. A number of mutant alleles have been identified, the commonest resulting in absence of the LDL receptors, while others result in reduced numbers or abnormal function of receptors. Heterozygotes have total serum cholesterol concentrations approximately double the normal range (7–3 mmol/l). In the homozygous state, which occurs in only one in a million of the population, the cholesterol concentrations are much higher, ranging from approximately 18 to 26 mmol/l.

In the normal individuals, raised concentrations of LDL in the circulation induce the formation of increased numbers of LDL receptors on cell surfaces. The majority of these receptors (50–75%) are located in the liver. Heterozygotes have only half the normal number of LDL receptors, and develop slowly progressive atherosclerosis, which usually becomes symptomatic in the fourth or fifth decade of life. In homozygotes, athrombosis progress much more rapidly, with symptoms of angina or even death occurring from coronary artery occlusions within the first two decades of life. The manifestations may include corneal stenosis of all three coronary arteries and the supravalvular aorta. He was referred to Cambridge for consideration of combined heart and liver transplantation. On cardiological review it was felt that because of his good left ventricular function bypass surgery would be appropriate. He had successful quadruple coronary artery bypass surgery and patch aortoplasty at Papworth Hospital. Two months later in November 1991 he received a liver graft without any anaesthetic or surgical problems. Apart from transient hypertension he had no post-operative problems and was discharged three weeks later with normal graft function and normal blood lipid concentrations.

**Patient 3**

This Greek boy developed extensive xanthomata from the age of 3 years and familial hypercholesterolaemia was diagnosed. He was treated with a low fat diet and cholestyramine but this had little effect on his cholesterol concentrations. From 11 years of age he developed exertional angina and was referred to the Brompton Hospital in London. An exercise stressed ECG showed severe ischaemic changes and coronary angiography demonstrated...
The formation of tuberous xanthoma over tendons and pressure areas.

Treatment options for familial hypercholesterolaemia include diet, drugs, plasmapheresis, bypass surgery, and liver transplantation. Since the gene has been localised, gene therapy may become the treatment of choice for the future. The first patient who has received successful ex vivo gene therapy has recently been reported.

Diet is of most benefit to patients with mildly raised serum lipids and has only a supporting role in the treatment of familial hypercholesterolaemia. Drugs used in the treatment of hypercholesterolaemia are of two main types: bile acid sequestrants and LDL receptor modifying agents. Bile acid sequestrants lower serum cholesterol by up to 20% and therefore are used as an adjunctive treatment in familial hypercholesterolaemia. They are also unpalatable, cause steatorrhoea, and prevent absorption of various nutrients, particularly the fat soluble vitamins. LDL receptor modifying agents are ineffective in this condition because the receptors are absent in homozygous familial hypercholesterolaemia.

Plasmapheresis removes cholesterol from the circulation and can lower the concentrations of two thirds of their pretreatment values. This remains a useful therapeutic option over the short term, chiefly to delay the development of atheroma before more definitive treatment. The effect of plasmapheresis is short lived, and requires twice weekly repetition to maintain satisfactory values; and there is the additional problem of long term venous access.

Partial ileal bypass, with a view to limiting the enterohepatic circulation of bile acids, has been described. This treatment was reported to lower serum cholesterol by a quarter to a third and so only delays the inevitable progression of atherosclerosis. It also has adverse effects on growth and development.

Portocaval shunting, initially reported by Starzl et al, reduces total and LDL cholesterol by approximately a third, through altering hepatic cholesterol and lipoprotein metabolism. This procedure requires major surgery and has inherent complications; in addition it may complicate later transplantation. In view of the complications inherent in these forms of surgery for familial hypercholesterolaemia, these procedures have been largely abandoned.

Liver transplantation is a therapeutic option for familial hypercholesterolaemia because the majority of LDL receptors are located in the liver and transplanted hepatocytes retain their original metabolic specificity. It was first described in a single patient in 1984, when a simultaneous heart transplant was performed. Since then three further patients have received combined liver and heart grafts. The use of coronary revascularisation has also been described. Heart transplantation is associated with accelerated coronary vascular atheroma. In those patients who survived a reduction of cholesterol to near normal values (an average reduction of pretransplant values) was recorded, one patient requiring further lipid lowering medication. There is also a report of a 4 year old child who received isolated liver transplantation followed by a fall in cholesterol values to within the normal range. In all three of our patients, the total and LDL cholesterol concentrations fell rapidly to normal and stayed there.

In conclusion, liver transplantation offers a highly effective treatment for this lethal condition and seems likely to remain the treatment of choice until gene therapy becomes a viable alternative. The timing of the operation is difficult but it should be considered once there is angiographic evidence of atheromatous disease, even in the absence of exertional angina. In well grown children with no previous abdominal surgery, the immediate risks of liver transplantation are low but long term complications such as chronic rejection remain a danger. After successful transplantation there may be a remarkable regression of established atheromatous lesions.

14 East C, Grundy SM, Bilheimer DW. Normal cholesterol levels with lovastatin (mevinolin) therapy in a child with homozygous familial hypercholesterolaemia following liver transplant. JAMA 1986; 256: 2843–8.
Liver transplantation for homozygous familial hypercholesterolaemia.

S P Revell, G Noble-Jamieson, P Johnston, A Rasmussen, N Jamieson and N D Barnes

Arch Dis Child 1995 73: 456-458
doi: 10.1136/adc.73.5.456

Updated information and services can be found at:
http://adc.bmj.com/content/73/5/456

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/